367 related articles for article (PubMed ID: 25935098)
1. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
3. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
[TBL] [Abstract][Full Text] [Related]
4. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
7. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
[TBL] [Abstract][Full Text] [Related]
9. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
10. Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy.
Kitazawa Y; Smith P; Sasaki N; Kotake S; Bae K; Iwamoto Y
Eye (Lond); 2011 Sep; 25(9):1161-9. PubMed ID: 21701528
[TBL] [Abstract][Full Text] [Related]
11. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
[TBL] [Abstract][Full Text] [Related]
12. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
14. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
15. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
16. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
[TBL] [Abstract][Full Text] [Related]
17. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
19. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
20. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
